Clinical Infectious Diseases · 2022 · 82 citations · 6 references
PharmacyInfectious DiseasesPharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiviral TherapyTreatmentViral PersistenceAntiviral Therapy De-escalationAntiviral Therapy DiscontinuationManagement Of High-risk PatientsTreatment Of Coronavirus InfectionsViral Infection TreatmentViral Kinetics
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
6
Nadège Néant, Guillaume Lingas, Quentin Le Hingrat et al. · Proceedings of the National Academy of Sciences · 2021 · 254 citations · Full text
Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson et al. · Mayo Clinic Proceedings · 2021 · 54 citations · Full text